Recapture remission in chronic idiopathic urticariaIn CIU, omalizumab retreatment recaptures remission in relapsers following drug withdrawal.
Secukinumab safe and effective through 5 years in psoriasisPatients were continually treated with the 300 mg for five years.
Cutaneous side effects of melanoma drugsDermatologists need “hands on” experience, researchers say at EADV 2017.
Avelumab safety profile is “acceptable”Immunotherapy improves Merkel cell carcinoma, but questions remain.
Update: Immunotherapeutic options in advanced melanomaAt EADV, Dr. Simone Ribero reviews the latest data on new treatments for advanced melanoma.
Oral baricitinib instead of topicals for atopic dermatitis?EADV study shows that this JAK inhibitor is a promising drug candidate in moderate-to-severe AD.
Azelaic acid reduces truncal acne
Azelaic acid reduces truncal acneA new azelaic acid 15% foam may provide a viable alternative to oral treatments for truncal acne.
Botanical ingredients reduce mild acne-related erythema
Botanical ingredients reduce mild acne-related erythemaA combination of salicylic acid and botanicals commonly may provide anti-inflammatory benefits as a spot treatment for acne.
Guselkumab front and center at EADV Congress
Guselkumab front and center at EADV CongressIL-23 inhibitors represent one more very effective strategy for controlling psoriasis with PASI rates comparable to other biologics.
Do we need pigment to develop melanoma?
Do we need pigment to develop melanoma?New insights into the pigment pathway are improving the understanding of how immunotherapy works in melanoma.